Abstract
Since the mid '90s, the concept of evidence-based medicine has grown exponentially, contributing to the advancement of personalized medicine, which considers the "female gender" as an extremely important area of customization, but orphan of targeted research. Strong evidence do exists demonstrating gender differences in bleeding risk associated with antithrombotic treatment, mostly related to lower values of body mass, organ size and renal function in women than men. Across clinical studies, the search for the specific risk of bleeding in the female vs male gender has gained attention only recently; therefore, data from different studies and relatively limited meta-analyses should be assessed carefully. As for antiplatelet therapy for primary prevention, the risk of major bleeding events, such as cerebral hemorrhage, is lower for women than for men. Conversely, in acute situations in which antithrombotic drugs are given in association, the risk of bleeding is greater for women, in particular for combination therapies with heparin or low molecular weight heparin or thrombolytic agents. Numerous studies in the literature evaluated the incidence of minor and major bleeding during oral anticoagulant therapy in relation to gender, but the results are not entirely consistent and appear to vary over the years. In summary, there are some aspects of guidance in the complex spectrum of the bleeding risk related to antithrombotic treatment, with indications of a lower bleeding risk in women than men related to long-term preventive single antithrombotic drug treatments. In addition, hormonal effects and use of outprescribed drugs may also play a significant role in modulating hemostasis.
| Original language | Italian |
|---|---|
| Pages (from-to) | 407-413 |
| Number of pages | 7 |
| Journal | Giornale Italiano di Cardiologia |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2012 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
I farmaci antitrombotici nella donna : Dobbiamo avere più paura delle emorragie? / Abbate, Rosanna; Cioni, Gabriele; Marcucci, Rossella; Fatini, Cinzia; Gensini, Gian Franco.
In: Giornale Italiano di Cardiologia, Vol. 13, No. 6, 06.2012, p. 407-413.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - I farmaci antitrombotici nella donna
T2 - Dobbiamo avere più paura delle emorragie?
AU - Abbate, Rosanna
AU - Cioni, Gabriele
AU - Marcucci, Rossella
AU - Fatini, Cinzia
AU - Gensini, Gian Franco
PY - 2012/6
Y1 - 2012/6
N2 - Since the mid '90s, the concept of evidence-based medicine has grown exponentially, contributing to the advancement of personalized medicine, which considers the "female gender" as an extremely important area of customization, but orphan of targeted research. Strong evidence do exists demonstrating gender differences in bleeding risk associated with antithrombotic treatment, mostly related to lower values of body mass, organ size and renal function in women than men. Across clinical studies, the search for the specific risk of bleeding in the female vs male gender has gained attention only recently; therefore, data from different studies and relatively limited meta-analyses should be assessed carefully. As for antiplatelet therapy for primary prevention, the risk of major bleeding events, such as cerebral hemorrhage, is lower for women than for men. Conversely, in acute situations in which antithrombotic drugs are given in association, the risk of bleeding is greater for women, in particular for combination therapies with heparin or low molecular weight heparin or thrombolytic agents. Numerous studies in the literature evaluated the incidence of minor and major bleeding during oral anticoagulant therapy in relation to gender, but the results are not entirely consistent and appear to vary over the years. In summary, there are some aspects of guidance in the complex spectrum of the bleeding risk related to antithrombotic treatment, with indications of a lower bleeding risk in women than men related to long-term preventive single antithrombotic drug treatments. In addition, hormonal effects and use of outprescribed drugs may also play a significant role in modulating hemostasis.
AB - Since the mid '90s, the concept of evidence-based medicine has grown exponentially, contributing to the advancement of personalized medicine, which considers the "female gender" as an extremely important area of customization, but orphan of targeted research. Strong evidence do exists demonstrating gender differences in bleeding risk associated with antithrombotic treatment, mostly related to lower values of body mass, organ size and renal function in women than men. Across clinical studies, the search for the specific risk of bleeding in the female vs male gender has gained attention only recently; therefore, data from different studies and relatively limited meta-analyses should be assessed carefully. As for antiplatelet therapy for primary prevention, the risk of major bleeding events, such as cerebral hemorrhage, is lower for women than for men. Conversely, in acute situations in which antithrombotic drugs are given in association, the risk of bleeding is greater for women, in particular for combination therapies with heparin or low molecular weight heparin or thrombolytic agents. Numerous studies in the literature evaluated the incidence of minor and major bleeding during oral anticoagulant therapy in relation to gender, but the results are not entirely consistent and appear to vary over the years. In summary, there are some aspects of guidance in the complex spectrum of the bleeding risk related to antithrombotic treatment, with indications of a lower bleeding risk in women than men related to long-term preventive single antithrombotic drug treatments. In addition, hormonal effects and use of outprescribed drugs may also play a significant role in modulating hemostasis.
KW - Antithrombotic drugs
KW - Bleeding
KW - Cardiovascular prevention
KW - Female gender
KW - Oral anticoagulant therapy
UR - http://www.scopus.com/inward/record.url?scp=84864799630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864799630&partnerID=8YFLogxK
U2 - 10.1714/1073.11758
DO - 10.1714/1073.11758
M3 - Articolo
C2 - 22622119
AN - SCOPUS:84864799630
VL - 13
SP - 407
EP - 413
JO - Giornale Italiano di Cardiologia
JF - Giornale Italiano di Cardiologia
SN - 1827-6806
IS - 6
ER -